Long-term deaths from melanoma according to tumor thickness at diagnosis.
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
12
12
2019
revised:
30
01
2020
accepted:
10
02
2020
pubmed:
19
2
2020
medline:
7
4
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
There is little long-term follow-up information about how the number of melanoma deaths and case fatality vary over time according to the measured thickness of melanoma at diagnosis. This population-based longitudinal cohort study examines patterns and trends in case fatality among 44,531 people in Queensland (Australia) diagnosed with a single invasive melanoma (International Classification of Diseases for Oncology, third revision [ICD-O-3], C44, Morphology 872-879) between 1987 and 2011, including 11,883 diagnosed between 1987 and 1996, with up to 20 years follow-up (to December 2016). The 20-year case fatality increased by thickness, with the percentage of melanoma deaths within 20 years of diagnosis being up to 4.8% for melanomas with measured thickness <0.80 mm, 10.6% for tumors 0.8 to <1.0 mm and generally more than 30% for melanomas measuring 3 mm and more. For melanomas <1.0 mm, most deaths occurred between 5 and 20 years after diagnosis, whereas for thicker melanomas the reverse was true with most deaths occurring within the first 5 years. Five-year case fatality decreased over successive calendar time periods for melanomas <1.0 mm, but not for melanomas ≥1.0 mm. These findings demonstrate that the time course for fatal melanomas varies markedly according to tumor thickness at diagnosis. Improved understanding of the patient factors and characteristics of melanomas, in addition to tumor thickness, which increase the likelihood of progression, is needed to guide clinical diagnosis, communication with patients and ongoing surveillance pathways of patients with potentially fatal lesions.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1391-1396Informations de copyright
© 2020 UICC.
Références
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472-92.
Bray F, Colombet M, Mery L, et al. Cancer incidence in five continents, Vol. XI (electronic version) Lyon: International Agency for Research on Cancer, 2017. Available from: http://ci5.iarc.fr, accessed November 18, 2019.
Youlden DR, Baade PD, Soyer HP, et al. Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study. J Invest Dermatol 2016;136:2270-6.
Aitken JF, Youlden DR, Baade PD, et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer 2018;142:1528-35.
Janda M, Neale RE, Youl P, et al. Impact of a video-based intervention to improve the prevalence of skin self-examination in men 50 years or older: the randomized skin awareness trial. Arch Dermatol 2011;147:799-806.
Janda M, Youl P, Neale R, et al. Clinical skin examination outcomes after a video-based behavioral intervention: analysis from a randomized clinical trial. JAMA Dermatol 2014;150:372-9.
Bakos RM, Blumetti TP, Roldan-Marin R, et al. Noninvasive imaging tools in the diagnosis and treatment of skin cancers. Am J Clin Dermatol 2018;19:3-14.
Burton RC, Armstrong BK. Non-metastasizing melanoma? J Surg Oncol 1998;67:73-6.
de Menezes SL, Kelly JW, Wolfe R, et al. The increasing use of shave biopsy for diagnosing invasive melanoma in Australia. Med J Aust 2019;211:213-8.
Smithers BM, Hughes MC, Beesley VL, et al. Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk of spread, in Queensland, Australia. J Surg Oncol 2015;112:359-65.
Gibbs DC, Orlow I, Vernali S, et al. Inherited melanoma risk variants associated with histopathologically amelanotic melanoma. J Invest Dermatol 2019; pii: S0022-202X(19)33239-7. https://doi.org/10.1016/j.jid.2019.09.006. [Epub ahead of print].
Mishra K, Barnhill RL, Paddock LE, et al. Histopathologic variables differentially affect melanoma survival by age at diagnosis. Pigment Cell Melanoma Res 2019;32:593-600.
Baker SG, Kramer BS, Prorok PC. Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol 2002;2:11.
Kou K, Dasgupta P, Cramb SM, et al. Temporal trends in population-level cure of cancer: the Australian context. Cancer Epidemiol Biomarkers Prev 2020. https://doi.org/10.1158/1055-9965.EPI-19-0693. [Epub ahead of print].
Piffaretti C, Moreno-Betancur M, Lamarche-Vadel A, et al. Quantifying cause-related mortality by weighting multiple causes of death. Bull World Health Organ 2016;94: 870-9.
Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 2015;21:175-83.
Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 2018;18:130.
Rowe CJ, Tang F, Hughes MC, et al. Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma. Int J Cancer 2016;139:664-72.
Ellis R, Tang D, Nasr B, et al. Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American joint committee on cancer stage I melanomas. Br J Dermatol 2020;182:156-165.